5//SEC Filing
Xia Yu 5
Accession 0001999371-24-002333
CIK 0001599298other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:35 PM ET
Size
7.8 KB
Accession
0001999371-24-002333
Insider Transaction Report
Form 5
Xia Yu
Director
Transactions
- Purchase
Common Stock
2023-03-07$1.05/sh+21,523,530$22,599,707→ 21,523,530 total(indirect: Akeso, Inc.) - Purchase
Common Stock
2023-01-17$2.51/sh+10,000,000$25,100,000→ 10,000,000 total(indirect: Akeso, Inc.)
Footnotes (3)
- [F1]21,523,530 shares of the Issuer's Common Stock were acquired on March 7, 2023 through a rights offering.
- [F2]10,000,000 shares of the Issuer's Common Stock were issued on January 17, 2023 in connection with the Collaboration and License Agreement with Akeso, Inc.("Akeso") pursuant to which the Issuer issued Akeso such shares.
- [F3]Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 28.9% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest.
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001963544
Filing Metadata
- Form type
- 5
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 4:35 PM ET
- Size
- 7.8 KB